APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drug Conjugate (ADC)

Compare research editions
View pricing & licenses

Selected research

Industry Research

First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Research Report 2026

23 December 2025151 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drug Conjugate (ADC) Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drug Conjugate (ADC) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drug Conjugate (ADC) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC) include Arvinas, Bayer Corporation, Bicara Therapeutics, Fabhalta, Immatics, Litfulo, Lytgobi, Merus and Ogsiveo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global First in Class (FIC) Antibody Drug Conjugate (ADC) market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Company

Arvinas

Bayer Corporation

Bicara Therapeutics

Fabhalta

Immatics

Litfulo

Lytgobi

Merus

Ogsiveo

Pumis Biotechnology (BioNTech)

Regeneron Pharmaceuticals

Skyclary

Talvey

Telix

Truqap

Vertex Pharmaceuticals

AstraZeneca

Dizal Pharma

Shanghai Henlius Biotech, Inc.

GSK

Jiangsu Hengrui Medicine

Pfizer

Akeso, Inc

Lixin Pharmaceutical Technology

Johnson & Johnson

Beijing Hotgen Biotech

Suzhou Yilian Biopharmaceutical

Shenzhen Yipusheng

Foreseen Biotechnology

Suzhou Zejing Biopharmaceutical

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type

Small Molecule FIC Drugs

Large Molecule FIC Drugs

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application

Tumors and Cancers

Others

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drug Conjugate (ADC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drug Conjugate (ADC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drug Conjugate (ADC) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of First in Class (FIC) Antibody Drug Conjugate (ADC) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of First in Class (FIC) Antibody Drug Conjugate (ADC) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units) of Manufacturers (2021-2026) Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Manufacturers (2021-2026) Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue of Manufacturers (2021-2026) Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Product Type & Application Table 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global First in Class (FIC) Antibody Drug Conjugate (ADC) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Arvinas Company Information Table 19. Arvinas Business Overview Table 20. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 22. Arvinas Recent Developments Table 23. Bayer Corporation Company Information Table 24. Bayer Corporation Business Overview Table 25. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 27. Bayer Corporation Recent Developments Table 28. Bicara Therapeutics Company Information Table 29. Bicara Therapeutics Business Overview Table 30. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 32. Bicara Therapeutics Recent Developments Table 33. Fabhalta Company Information Table 34. Fabhalta Business Overview Table 35. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 37. Fabhalta Recent Developments Table 38. Immatics Company Information Table 39. Immatics Business Overview Table 40. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 42. Immatics Recent Developments Table 43. Litfulo Company Information Table 44. Litfulo Business Overview Table 45. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 47. Litfulo Recent Developments Table 48. Lytgobi Company Information Table 49. Lytgobi Business Overview Table 50. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 52. Lytgobi Recent Developments Table 53. Merus Company Information Table 54. Merus Business Overview Table 55. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 57. Merus Recent Developments Table 58. Ogsiveo Company Information Table 59. Ogsiveo Business Overview Table 60. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 62. Ogsiveo Recent Developments Table 63. Pumis Biotechnology (BioNTech) Company Information Table 64. Pumis Biotechnology (BioNTech) Business Overview Table 65. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 67. Pumis Biotechnology (BioNTech) Recent Developments Table 68. Regeneron Pharmaceuticals Company Information Table 69. Regeneron Pharmaceuticals Business Overview Table 70. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 72. Regeneron Pharmaceuticals Recent Developments Table 73. Skyclary Company Information Table 74. Skyclary Business Overview Table 75. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 77. Skyclary Recent Developments Table 78. Talvey Company Information Table 79. Talvey Business Overview Table 80. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 82. Talvey Recent Developments Table 83. Telix Company Information Table 84. Telix Business Overview Table 85. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 87. Telix Recent Developments Table 88. Truqap Company Information Table 89. Truqap Business Overview Table 90. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 92. Truqap Recent Developments Table 93. Vertex Pharmaceuticals Company Information Table 94. Vertex Pharmaceuticals Business Overview Table 95. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 97. Vertex Pharmaceuticals Recent Developments Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 102. AstraZeneca Recent Developments Table 103. Dizal Pharma Company Information Table 104. Dizal Pharma Business Overview Table 105. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 107. Dizal Pharma Recent Developments Table 108. Shanghai Henlius Biotech, Inc. Company Information Table 109. Shanghai Henlius Biotech, Inc. Business Overview Table 110. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 112. Shanghai Henlius Biotech, Inc. Recent Developments Table 113. GSK Company Information Table 114. GSK Business Overview Table 115. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 117. GSK Recent Developments Table 118. Jiangsu Hengrui Medicine Company Information Table 119. Jiangsu Hengrui Medicine Business Overview Table 120. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 122. Jiangsu Hengrui Medicine Recent Developments Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 127. Pfizer Recent Developments Table 128. Akeso, Inc Company Information Table 129. Akeso, Inc Business Overview Table 130. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 132. Akeso, Inc Recent Developments Table 133. Lixin Pharmaceutical Technology Company Information Table 134. Lixin Pharmaceutical Technology Business Overview Table 135. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 137. Lixin Pharmaceutical Technology Recent Developments Table 138. Johnson & Johnson Company Information Table 139. Johnson & Johnson Business Overview Table 140. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 142. Johnson & Johnson Recent Developments Table 143. Beijing Hotgen Biotech Company Information Table 144. Beijing Hotgen Biotech Business Overview Table 145. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 147. Beijing Hotgen Biotech Recent Developments Table 148. Suzhou Yilian Biopharmaceutical Company Information Table 149. Suzhou Yilian Biopharmaceutical Business Overview Table 150. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 152. Suzhou Yilian Biopharmaceutical Recent Developments Table 153. Shenzhen Yipusheng Company Information Table 154. Shenzhen Yipusheng Business Overview Table 155. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 157. Shenzhen Yipusheng Recent Developments Table 158. Foreseen Biotechnology Company Information Table 159. Foreseen Biotechnology Business Overview Table 160. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 162. Foreseen Biotechnology Recent Developments Table 163. Suzhou Zejing Biopharmaceutical Company Information Table 164. Suzhou Zejing Biopharmaceutical Business Overview Table 165. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 167. Suzhou Zejing Biopharmaceutical Recent Developments Table 168. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026) & (k units) Table 170. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2021-2026) Table 171. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2027-2032) & (k units) Table 172. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2027-2032) Table 173. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2021-2026) & (US$ Million) Table 174. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2021-2026) Table 175. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region (2027-2032) & (US$ Million) Table 176. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2027-2032) Table 177. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 179. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 180. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2026) & (US$ Million) Table 181. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 184. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 185. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 189. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 190. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2027-2032) & (US$ Million) Table 192. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 194. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 195. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2026) & (US$ Million) Table 196. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 199. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2027-2032) & (k units) Table 200. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2027-2032) & (US$ Million) Table 202. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 203. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2027-2032) & (k units) Table 204. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2026) Table 205. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2027-2032) Table 206. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021-2026) & (US$ Million) Table 207. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2027-2032) & (US$ Million) Table 208. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2026) Table 209. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2027-2032) Table 210. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2021-2026) & (USD/unit) Table 211. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2027-2032) & (USD/unit) Table 212. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 213. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2027-2032) & (k units) Table 214. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2026) Table 215. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2027-2032) Table 216. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021-2026) & (US$ Million) Table 217. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2027-2032) & (US$ Million) Table 218. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2026) Table 219. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2027-2032) Table 220. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Application (2021-2026) & (USD/unit) Table 221. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Application (2027-2032) & (USD/unit) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors List Table 225. First in Class (FIC) Antibody Drug Conjugate (ADC) Customers List Table 226. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends Table 227. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers Table 228. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Image Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (2021-2032) & (US$ Million) Figure 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2032) & (k units) Figure 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/unit) & (2021-2032) Figure 9. Small Molecule FIC Drugs Product Image Figure 10. Large Molecule FIC Drugs Product Image Figure 11. Tumors and Cancers Product Image Figure 12. Others Product Image Figure 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region in 2025 Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region in 2025 Figure 20. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2025 Figure 21. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 22. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Country (2021-2032) Figure 23. United States First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2025 Figure 27. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 28. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Country (2021-2032) Figure 29. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2025 Figure 40. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Country (2021-2032) Figure 42. China First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2025 Figure 51. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 52. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Country (2021-2032) Figure 53. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2025 Figure 57. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Country (2021-2032) Figure 59. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2032) Figure 65. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2032) Figure 66. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price (USD/unit) by Type (2021-2032) Figure 67. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2032) Figure 68. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2032) Figure 69. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price (USD/unit) by Application (2021-2032) Figure 70. First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Figure 71. First in Class (FIC) Antibody Drug Conjugate (ADC) Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Small Molecule FIC Drugs
  • Large Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Others
Companies covered
  • Arvinas
  • Bayer Corporation
  • Bicara Therapeutics
  • Fabhalta
  • Immatics
  • Litfulo
  • Lytgobi
  • Merus
  • Ogsiveo
  • Pumis Biotechnology (BioNTech)
  • Regeneron Pharmaceuticals
  • Skyclary
  • Talvey
  • Telix
  • Truqap
  • Vertex Pharmaceuticals
  • AstraZeneca
  • Dizal Pharma
  • Shanghai Henlius Biotech, Inc.
  • GSK
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Akeso, Inc
  • Lixin Pharmaceutical Technology
  • Johnson & Johnson
  • Beijing Hotgen Biotech
  • Suzhou Yilian Biopharmaceutical
  • Shenzhen Yipusheng
  • Foreseen Biotechnology
  • Suzhou Zejing Biopharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (2021-2032)
  4. 2.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2032)
  5. 2.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Average Price (2021-2032)
  6. 2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Small Molecule FIC Drugs
  9. 2.3.3 Large Molecule FIC Drugs
  10. 2.4 First in Class (FIC) Antibody Drug Conjugate (ADC) by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Tumors and Cancers
  13. 2.4.3 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Product Type & Application
  8. 3.8 Global Manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC), Established Date
  9. 3.9 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Arvinas
  2. 4.1.1 Arvinas Company Information
  3. 4.1.2 Arvinas Business Overview
  4. 4.1.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  6. 4.1.5 Arvinas Recent Developments
  7. 4.2 Bayer Corporation
  8. 4.2.1 Bayer Corporation Company Information
  9. 4.2.2 Bayer Corporation Business Overview
  10. 4.2.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  12. 4.2.5 Bayer Corporation Recent Developments
  13. 4.3 Bicara Therapeutics
  14. 4.3.1 Bicara Therapeutics Company Information
  15. 4.3.2 Bicara Therapeutics Business Overview
  16. 4.3.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  18. 4.3.5 Bicara Therapeutics Recent Developments
  19. 4.4 Fabhalta
  20. 4.4.1 Fabhalta Company Information
  21. 4.4.2 Fabhalta Business Overview
  22. 4.4.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  24. 4.4.5 Fabhalta Recent Developments
  25. 4.5 Immatics
  26. 4.5.1 Immatics Company Information
  27. 4.5.2 Immatics Business Overview
  28. 4.5.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  30. 4.5.5 Immatics Recent Developments
  31. 4.6 Litfulo
  32. 4.6.1 Litfulo Company Information
  33. 4.6.2 Litfulo Business Overview
  34. 4.6.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  36. 4.6.5 Litfulo Recent Developments
  37. 4.7 Lytgobi
  38. 4.7.1 Lytgobi Company Information
  39. 4.7.2 Lytgobi Business Overview
  40. 4.7.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  42. 4.7.5 Lytgobi Recent Developments
  43. 4.8 Merus
  44. 4.8.1 Merus Company Information
  45. 4.8.2 Merus Business Overview
  46. 4.8.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  48. 4.8.5 Merus Recent Developments
  49. 4.9 Ogsiveo
  50. 4.9.1 Ogsiveo Company Information
  51. 4.9.2 Ogsiveo Business Overview
  52. 4.9.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  54. 4.9.5 Ogsiveo Recent Developments
  55. 4.10 Pumis Biotechnology (BioNTech)
  56. 4.10.1 Pumis Biotechnology (BioNTech) Company Information
  57. 4.10.2 Pumis Biotechnology (BioNTech) Business Overview
  58. 4.10.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  60. 4.10.5 Pumis Biotechnology (BioNTech) Recent Developments
  61. 4.11 Regeneron Pharmaceuticals
  62. 4.11.1 Regeneron Pharmaceuticals Company Information
  63. 4.11.2 Regeneron Pharmaceuticals Business Overview
  64. 4.11.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  66. 4.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 4.12 Skyclary
  68. 4.12.1 Skyclary Company Information
  69. 4.12.2 Skyclary Business Overview
  70. 4.12.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  72. 4.12.5 Skyclary Recent Developments
  73. 4.13 Talvey
  74. 4.13.1 Talvey Company Information
  75. 4.13.2 Talvey Business Overview
  76. 4.13.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  78. 4.13.5 Talvey Recent Developments
  79. 4.14 Telix
  80. 4.14.1 Telix Company Information
  81. 4.14.2 Telix Business Overview
  82. 4.14.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  84. 4.14.5 Telix Recent Developments
  85. 4.15 Truqap
  86. 4.15.1 Truqap Company Information
  87. 4.15.2 Truqap Business Overview
  88. 4.15.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  90. 4.15.5 Truqap Recent Developments
  91. 4.16 Vertex Pharmaceuticals
  92. 4.16.1 Vertex Pharmaceuticals Company Information
  93. 4.16.2 Vertex Pharmaceuticals Business Overview
  94. 4.16.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  96. 4.16.5 Vertex Pharmaceuticals Recent Developments
  97. 4.17 AstraZeneca
  98. 4.17.1 AstraZeneca Company Information
  99. 4.17.2 AstraZeneca Business Overview
  100. 4.17.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  102. 4.17.5 AstraZeneca Recent Developments
  103. 4.18 Dizal Pharma
  104. 4.18.1 Dizal Pharma Company Information
  105. 4.18.2 Dizal Pharma Business Overview
  106. 4.18.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  108. 4.18.5 Dizal Pharma Recent Developments
  109. 4.19 Shanghai Henlius Biotech, Inc.
  110. 4.19.1 Shanghai Henlius Biotech, Inc. Company Information
  111. 4.19.2 Shanghai Henlius Biotech, Inc. Business Overview
  112. 4.19.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  114. 4.19.5 Shanghai Henlius Biotech, Inc. Recent Developments
  115. 4.20 GSK
  116. 4.20.1 GSK Company Information
  117. 4.20.2 GSK Business Overview
  118. 4.20.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  120. 4.20.5 GSK Recent Developments
  121. 4.21 Jiangsu Hengrui Medicine
  122. 4.21.1 Jiangsu Hengrui Medicine Company Information
  123. 4.21.2 Jiangsu Hengrui Medicine Business Overview
  124. 4.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  126. 4.21.5 Jiangsu Hengrui Medicine Recent Developments
  127. 4.22 Pfizer
  128. 4.22.1 Pfizer Company Information
  129. 4.22.2 Pfizer Business Overview
  130. 4.22.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  132. 4.22.5 Pfizer Recent Developments
  133. 4.23 Akeso, Inc
  134. 4.23.1 Akeso, Inc Company Information
  135. 4.23.2 Akeso, Inc Business Overview
  136. 4.23.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  138. 4.23.5 Akeso, Inc Recent Developments
  139. 4.24 Lixin Pharmaceutical Technology
  140. 4.24.1 Lixin Pharmaceutical Technology Company Information
  141. 4.24.2 Lixin Pharmaceutical Technology Business Overview
  142. 4.24.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  144. 4.24.5 Lixin Pharmaceutical Technology Recent Developments
  145. 4.25 Johnson & Johnson
  146. 4.25.1 Johnson & Johnson Company Information
  147. 4.25.2 Johnson & Johnson Business Overview
  148. 4.25.3 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  150. 4.25.5 Johnson & Johnson Recent Developments
  151. 4.26 Beijing Hotgen Biotech
  152. 4.26.1 Beijing Hotgen Biotech Company Information
  153. 4.26.2 Beijing Hotgen Biotech Business Overview
  154. 4.26.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  156. 4.26.5 Beijing Hotgen Biotech Recent Developments
  157. 4.27 Suzhou Yilian Biopharmaceutical
  158. 4.27.1 Suzhou Yilian Biopharmaceutical Company Information
  159. 4.27.2 Suzhou Yilian Biopharmaceutical Business Overview
  160. 4.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  162. 4.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
  163. 4.28 Shenzhen Yipusheng
  164. 4.28.1 Shenzhen Yipusheng Company Information
  165. 4.28.2 Shenzhen Yipusheng Business Overview
  166. 4.28.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  168. 4.28.5 Shenzhen Yipusheng Recent Developments
  169. 4.29 Foreseen Biotechnology
  170. 4.29.1 Foreseen Biotechnology Company Information
  171. 4.29.2 Foreseen Biotechnology Business Overview
  172. 4.29.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  174. 4.29.5 Foreseen Biotechnology Recent Developments
  175. 4.30 Suzhou Zejing Biopharmaceutical
  176. 4.30.1 Suzhou Zejing Biopharmaceutical Company Information
  177. 4.30.2 Suzhou Zejing Biopharmaceutical Business Overview
  178. 4.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  180. 4.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Scenario by Region
  1. 5.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021-2032
  3. 5.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2021-2026
  4. 5.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region: 2027-2032
  5. 5.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region: 2021-2032
  6. 5.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region: 2021-2026
  7. 5.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Region: 2027-2032
  8. 5.4 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Facts & Figures by Country
  9. 5.4.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  11. 5.4.3 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Facts & Figures by Country
  16. 5.5.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  18. 5.5.3 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Facts & Figures by Country
  41. 5.7.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  43. 5.7.3 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2032)
  2. 6.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2021-2032)
  4. 6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Type (2021-2032)
  5. 6.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2032)
  2. 7.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2021-2032)
  4. 7.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue by Application (2021-2032)
  5. 7.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Analysis
  2. 8.1.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Production Mode & Process
  5. 8.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors
  8. 8.2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Customers
9 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Analyzing Market Dynamics
  1. 9.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends
  2. 9.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers
  3. 9.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges
  4. 9.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst